Leerink Partners Upgrades Design Therapeutics Inc (DSGN) to Outperform

Leerink Partners analyst Joseph Schwartz upgraded Design Therapeutics Inc (NASDAQ: DSGN) from Market Perform to Outperform with a price target of $14.00.

The analyst comments "We are upgrading Design (DSGN) to Outperform from Market Perform. After PK and safety issues arose with the first-generation asset for Friedreich's Ataxia (FA) in 2023, the company needed to pivot to a new formulation, DT-216P2. After making these changes and demonstrating improved PK in NHPs and healthy volunteers, we finally have line of sight to data in 2H26. We are also intrigued by the recently unveiled candidate, DT-818, for myotonic dystrophy type 1 (DM1), which could capitalize on the interest in the space (here) with a differentiated and potentially best-in-class approach. Our PT moves to $14 (from $7)."

For an analyst ratings summary and ratings history on Design Therapeutics Inc click here. For more ratings news on Design Therapeutics Inc click here.

Shares of Design Therapeutics Inc closed at $8.94 yesterday.

You May Also Be Interested In

• Varonis Systems (VRNS) 1500 contracts of June 70 calls trade, share price up 11.5%
• PVH Corp. (PVH) Tops Q2 EPS by 62c, Beats on Revenue; Offers FY27 EPS Guidance
• Evercore ISI: 'AAPL has so far offset softer App Store trends with faster-growing areas'